Back to News
Market Impact: 0.25
Stoke And Biogen Unveil Long-Term Zorevunersen Data In Dravet Syndrome
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsProduct Launches
Stoke Therapeutics (STOK) and Biogen (BIIB) announced new long-term findings for zorevunersen in patients with Dravet syndrome, to be presented at the 16th European Epilepsy Congress in Athens. The update is a positive clinical-development milestone, though no efficacy/safety figures were provided in the news item. Expected impact is modest absent reported results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
BIIB0.25
STOK0.25
More News
- Indonesian stocks plunge to six-year low as MSCI downgrade fears mount
- China's CXMT sees shares drop over 6% as investors look past chipmaker's profit turnaround
- Australia’s Cleanaway agrees to $6.5 bln EQT buyout bid; shares surge
- India’s Finance Minister blames easy exits and excess liquidity for equity market's underperformance
- Zoom and big financial firms add ‘Proof of Human’ badges from Sam Altman’s World to stop fraud and deep fakes
- Daiichi Life Offers to Buy Remainder of Australia’s Challenger